Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07285291
PHASE3

A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders

Sponsor: Taisho Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

A phase 3, randomized, placebo-controlled, double-blind, phosphate binder-combination study of TS-172 in hyperphosphatemia patients on hemodialysis

Official title: A Phase 3, Randomized, Placebo-controlled, Double-blind, Phosphate Binder-combination Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2026-01-05

Completion Date

2026-12-29

Last Updated

2026-01-09

Healthy Volunteers

No

Interventions

DRUG

TS-172 20~60 mg/day

oral administration of TS-172 20\~60 mg/day

DRUG

Placebo

oral administration of placebo

Locations (1)

Taisho Pharmaceutical Co., Ltd selected site

Tokyo, Japan